ClinicalTrials.govpublic full text
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
melanoma, acral melanoma, temozolomide, apatinib, camrelizumab, neoadjuvant, pathological response, immune checkpoint inhibitors, protein kinase inhibitors, antineoplastic agents, alkylating, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 914260
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.